Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 8:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 10,347 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all
Terminated Phase 1 Interventional

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

NCT02292225
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic
Interventions
IPI-145 (duvelisib), Obinutuzumab
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Nov 1, 2026, 8:34 PM EST
Recruiting No phase listed Observational

Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy

NCT06646640
View directory record Official record
Conditions
Hemoglobin Disorder
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2050
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 1, 2026, 8:34 PM EST
Withdrawn Phase 1 Interventional

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

NCT01130623
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
Interventions
Pazopanib (GW786034)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 1, 2026, 8:34 PM EST
Completed Phase 3 Interventional Results available

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

NCT03068780
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Oleogel-S10, Control gel
Drug
Lead sponsor
Amryt Research Limited
Industry
Eligibility
21 Days and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Aurora, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Nov 1, 2026, 8:34 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

NCT00407979
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Nov 1, 2026, 8:34 PM EST
Completed No phase listed Observational

Diffuse Myocardial Fibrosis in Fontan Patients

NCT01929174
View directory record Official record
Conditions
Congenital Heart Disease, Single Ventricle, Myocardial Fibrosis
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Nov 1, 2026, 8:34 PM EST
Completed Phase 4 Interventional Results available

Standardized Treatment of Pulmonary Exacerbations II

NCT02781610
View directory record Official record
Conditions
Pulmonary Cystic Fibrosis
Interventions
Standard of care IV antibiotic(s)
Drug
Lead sponsor
Chris Goss
Other
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
57
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Nov 1, 2026, 8:34 PM EST
Completed No phase listed Observational Results available

Ondansetron and the QT Interval In Adult Emergency Department Patients

NCT01759420
View directory record Official record
Conditions
Ondansetron
Interventions
Ondansetron
Drug
Lead sponsor
C.R.Darnall Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Fort Hood, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Nov 1, 2026, 8:34 PM EST
Active, not recruiting No phase listed Observational

Prospective Study of Pregnancy in Women With Cystic Fibrosis

NCT04828382
View directory record Official record
Conditions
Pregnancy Related, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Amalia Magaret
Other
Eligibility
16 Years and older · Female only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Nov 1, 2026, 8:34 PM EST
Completed Phase 4 Interventional

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

NCT07076446
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Centennial, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 1, 2026, 8:34 PM EST
Completed Not applicable Interventional

Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease

NCT01656746
View directory record Official record
Conditions
Adenomatous Polyp, Crohn Disease, Familial Adenomatous Polyposis, Hereditary Intestinal Polyposis Syndrome, Recurrent Colon Cancer, Stage I Colon Cancer, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer
Interventions
therapeutic laparoscopic surgery
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Nov 1, 2026, 8:34 PM EST
Completed Not applicable Interventional

Pharmacokinetics and Pharmacodynamics of Anthocyanins

NCT03650140
View directory record Official record
Conditions
Gout
Interventions
Tart cherry extract 60 mL, Tart cherry extract 120 mL
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Nov 1, 2026, 8:34 PM EST
Completed Phase 2 Interventional

RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants

NCT02178189
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
High Calorie Infant formula, Standard Calorie Infant Formula
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
1 Day to 3 Days
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Nov 1, 2026, 8:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome

NCT02368379
View directory record Official record
Conditions
Prader Willi Syndrome, Adrenal Insufficiency
Interventions
Low dose (1 mcg) ACTH stimulation test, Overnight metyrapone test
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Nov 1, 2026, 8:34 PM EST
Recruiting Phase 1Phase 2 Interventional

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

NCT06834035
View directory record Official record
Conditions
Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions
Immunoglobulin G
Biological
Lead sponsor
M. Peter Marinkovich
Other
Eligibility
6 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 1, 2026, 8:34 PM EST
Completed Not applicable Interventional

Effect of Caudal and Penile Block on Hypospadias Repair Complications

NCT02851290
View directory record Official record
Conditions
Hypospadias
Interventions
Caudal block anesthesia, Dorsal penile nerve block anesthesia
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Months to 4 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Nov 1, 2026, 8:34 PM EST
Completed Phase 2Phase 3 Interventional

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

NCT01625390
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
BAY86-6150, eptacog alfa [activated]
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 62 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Sacramento, California • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Nov 1, 2026, 8:34 PM EST
Enrolling by invitation Not applicable Interventional

Heart2Heart for Teens With CHD

NCT07764510
View directory record Official record
Conditions
Congenital Heart Disease, Health Behavior
Interventions
Heart2Heart
Behavioral
Lead sponsor
Kristen Fox
Other
Eligibility
12 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 1, 2026, 8:34 PM EST
Active, not recruiting Phase 3 Interventional

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

NCT05367960
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Zatolmilast/ BPN14770
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
9 Years to 45 Years · Male only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Irvine, California • Orange, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 1, 2026, 8:34 PM EST
Completed No phase listed Observational

Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus.

NCT03277768
View directory record Official record
Conditions
Premature Infant, Patent Ductus Arteriosus, Hemodynamic Instability
Interventions
Resonance Raman Spectroscopy (RRS)
Device
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
55 participants
Timeline
2015 – 2018
U.S. locations
2
States / cities
Gainesville, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Nov 1, 2026, 8:34 PM EST
Terminated No phase listed Observational

B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease

NCT02316691
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Nov 1, 2026, 8:34 PM EST
Completed Phase 1Phase 2 Interventional Results available

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

NCT00519818
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency, Adrenogenital Syndrome
Interventions
Chronocort, Cortef
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Nov 1, 2026, 8:34 PM EST
Completed Phase 2Phase 3 Interventional

High Dose Ascorbic Acid Treatment of CMT1A

NCT00484510
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease, Type Ia
Interventions
Ascorbic acid (Vitamin C), placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
13 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Baltimore, Maryland • Detroit, Michigan • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Nov 1, 2026, 8:34 PM EST
Active, not recruiting Phase 3 Interventional

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

NCT06246513
View directory record Official record
Conditions
Limb-girdle Muscular Dystrophy
Interventions
SRP-9003, Glucocorticoid
Biological · Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
La Jolla, California • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 1, 2026, 8:34 PM EST